GW Pharmaceuticals, the British maker of epileptic seizure-control medication Epidiolex, said it was not aware of any supply issues related to the cannabis-derived drug... GW Pharma denies supply issues with cannabis-based drug Epidiolex after stock falls

GW Pharmaceuticals, the British maker of epileptic seizure-control medication Epidiolex, said it was not aware of any supply issues related to the cannabis-derived drug after a tweet from a patient’s father complained he could not source the medicine.

GW’s stock was down more than 3% on Wednesday on the Nasdaq after the tweet from San Francisco Bay Area journalist Ryan Flinn, who complained that his daughter had suffered four seizures since local pharmacies and her doctor had been unable to refill the prescription.

The stock declined further early Thursday before trimming some of the losses mid-morning.

Company spokesman Steve Schultz said there were no supply issues relating to Epidiolex but did admit to some issues with insurance companies, according to a report Wednesday by New Cannabis Ventures.

Flinn tweeted Thursday that his daughter’s Epidiolex had arrived “after 19 calls + 338 min on phone. Still not clear on hold up.”

United Kingdom-based GW trades on the Nasdaq under the ticker GWPH.

Subscribe to our Newsletter

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

No comments so far.

Be first to leave comment below.

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )